The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
This is an exciting and meaningful milestone for GRIN Therapeutics
The Danish biotech company confirmed the global study will begin in the second half of 2026
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
